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Orthotopic Liver Transplantation for Fulminant 
and Subacute Hepatic Failure 
ANDREI C. STIEBER, SHU,,"ZABURQ IWATSUKI, AND THOMAS E. STARZL 
Fulminant and subacute hepatitis ue conditions character-
ized by rapid Ii .. er failure, which can lead to death in 80 to 
more than 95% of the cases with medical supportive care 
only. The etiology can be .. ira I, drug., or other chemical·in-
duced, metabolic, etc. Orthotopic li .. er transplantation 
emerged during the 1980s as a powerful means for dealing 
with these diseases. The existence of this therapeutic mo-
dality has brought about major changes in the diagnosis, 
patient selection, treatment, and outlook for fulminant! 
subacute liver failure. The .luthors present the results of 
orthotopic liver transplantation for the heatment of 47 
cases of acute/subacute hepatic insufficiency at the Univer-
sity of Pittsburgh between March 19~l and July 1987. The 
results of this series demonstrate that Ii .. er transplantation 
is the most eff ecli .. e means for treating this condition. 
"($AIO Transflctions 1988; 34: 959-964. 
Fulminant and subacute hepatiC failure (FHF /5AF) are 
conditions characterized by diffuse necrosis of hepatiC par· 
enchyma, due to any number of liver insults (in order of 
frequency: viral infectiOns. chemICals and tOJ(lnS, metabolic 
disorders, and others!. Hepatic failure is defined as fulmi· 
nan! when II occurs Within 8 \\eeks oi the onset oi the 
symptoms and subacute when the hepatic Insufficiency 
manifests Itself sometime between the 8th and 20th .. o,eek 
after onset of the s) mptoms of liller disease, 
True FHF presents with progressive and rapid deteriora-
tion of hepatic function, leading to deepening jaundice. 
acute onset and progression oi hepatiC encephalopathy. 
"foetor hepaticus," ascites, edema, severe derangement of 
clotling and, In the later stages, hepatorenal syndrome. 
sepsis, hypogl) cemla, acidosis. multiorgan failure. and 
ell'entual death. True FHF is a s .. ndrome with an exceedingly 
advanced degree oj morbidity and mortality. The mortality 
is age· and etiology-dependent and is approJ(imately 80% 
when stage IV coma has been reached. despite intensive 
and sophisticated medical care.'·4 In adult patients. reach-
ing stage IV coma raises the mortality rate to 95% or more. 
On the other hand, SAF has a slower evolution. although 
with a similar outcome in most cases. 
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In this context. transplantation of the liver (ortho- or het-
erotopic) was a tempting alternative to non-operative (medi-
cal) therapy since the very beginning of trials with hepatic 
replacement in humans. Unfortunately. ttie poor results ob-
tained with liver transplantation throughout the 1960s and 
1970s blunted the efforts of organ replacement (or patients 
with acute liver failure. In faet. it is only recently that whole 
organ liver replacement has achieved a success rate justify. 
ing its use (or FHF/SAF.l-S 
We describe our experience with the pre-. intra-. and 
postoperative evaluation. management. and decision-mak. 
ing process with regard to liller transplantation in patients 
with FHF and SAF. A presentation of the results achieved by 
our group with orthotopic liver transplantation for FHF /5M 
..... ill then follow. 
Etiology 
A large number of causes for FHF have been identified. In 
order o( their frequency. they are: VIruses (hepatitis A. B, 
and non-A. non·B), tOXIC substances (e.g .• acetominophen). 
volatile solvents and anesthetic agents (e g. halothane) and 
a iew metabolic disorders (especially fulminant Wilson's 
disease!. Despite intenSive medical treatment. most patients 
"" ith chemically-induced hepatitis. halothane hepatitis. and 
most cases of fulminant viral hepatitis die (>95%) without 
liver replacement.'; In the case of fulminant Wilson's dis-
ease, the mortality with non-operative treatment is 100%. 
Consequently. it is of the utmost importance and urgency to 
establish the etiology of the liver failure to be in a position to 
decide"" hether or not and when to advise and proceed with 
liver transplantation. Similar considerations applv for SAF. 
although the sense of urgency is somewhat reduced. 
Preoperative Evaluation .lnd Management 
Fulminant hepatic necrosis is generally the consequence 
of viral infection (type A. B, or non-A. non-8) or chemical 
insult. either (rom drugs (involving overdosage or hypersen. 
sitivity) or from toxic agents. Establishing an etiology is im. 
portant not only from an academic point of view but also to 
guide therapy. avoid further parenchymal damage, and 
make a prognosis. An attentive history and a high degree o( 
suspicion will, as a rule. reveal iIIny recent exposure to drugs 
or other chemicals. or any risk 'illetors for contracting viral 
hepatitis. A family history of liver failure and/or severe neu· 
rologic disorders may provide a clue illS to the possibility 
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Figur. 1. As liver insufficiency progresses, the indications fOf 
transplantation increase. up to a potnt where the degree of in-evers-
ibohty of the coma causes these indicahons to decrease as a result of 
unacceptable mort::)ldity/mortaJity, 
of fulminant Wilson's disease as the etiology (or hepatic 
(ailure. 
As soon as the patient is admitted, a complete serologic 
profile (or viral liver disease (A •. B. non-A/non-8, Epstein-
Barr virus, Herpes simplex virus, and cytomegalovirus) is 
done; a toxin screen and the measurement o( urinary cop-
per and serum ceruloplasmin levels are done as well. Mas-
sl\e hemolysis and renal failure of recent onset are strongly 
suggestive oi fulmmant Wilson's disease·" or of hepatitis 
assOCiated With glucose-6-phosphatase deficiency. On the 
other hand, granulocytopenia with or Without Iymphocy-
tom suggests fulminant non-A, non-B hepatitis or one of the 
other more mfrequent causes of viral hepatitis. 
Next, the tentative determination of the prognosis is fun-
damental in the decision of whether or not transplantation is 
indicated and. if it is, on what the right timing should be. 
Rapidly progressing encephalopathy, development of cere-
bral edema and/or a rapidly shrinking liver, severe hemo-
lysis. onset and progression of hepatorenal sYlldrome, and/ 
or deepening jaundice are all ominous signs and should alert 
physicians that irreversible liver damage is likely and liver 
transplantation is necessary and imminent (Figure 1). Trans-
plantation in the presence of grade IV coma, bacteremia, 
severe hepatorenal syndrome, spontaneous bacterial peri-
tonitis or other sepsis, and massive gastrointestinal hemor-
rhage has a very poor prognosis. This is why the decision to 
transplant a patient with FHF is one of the most difficult and 
agonizing that a physician will ever face. The favorable 
"window" for transplantation may be extremely brief and 
temporizing may compromise the patient's chance for sur-
vival (Figure 1). SpeCifically, rapid deepening of hepatic 
coma, a steady prolongation of the prothrombin time (which 
becomes unresponsive to infusion of fresh frozen plasma), 
the development of the hepatorenal syndrome, hypoglyce-
mia, and uncorrectable metaboliC acidosis are all signs of 
impending dealh, which can only be avoided by emergency 
fiver transplantation. Frequent evaluation o( the patient's 
condition, as often as hourly, is needed in such a situation to 
allow the phy~ician to make the correct decision. The deci-
sion to recommend and to proceed with hepatic transplan-
tation (or FHF or SAF (also called "late-onset hepatic (ail-
ure") IS less dliiicult no\\ adays, thanks to the vastly im-
proved results obtained with organ replacement. 
Another essential point is that patients with FHF must be 
placed on the urgent transplant list as soon as they are ad-
mitled to the hospital. Age, blood type, height, weight, and 
chest circumference must be obtained to permit a good 
donor/recipient match, if possible. Matching for blood type 
is desirable, although not essential; on the other hand, a 
good size match IS necessary for technical reasons, The 
clinical situation oi the patient must be assessed every time 
a potential donor organ becomes available, and a liver 
transplant should be done if the patient's condition is 
thought to be irre\ersible without organ replacement and if 
the donor is suitable. In particularly desperate situations, a 
liver that is of a different blood type and/or size can be 
used, e\en if such g~afts result in less than ideallransplant 
outcomes; a Ii.er thaI IS too large can be "trimmed" before 
implantation by rr.eans of a partial hepatectomy on the 
back-bench. In addition to the above mentioned blood 
tests, the work-up should include sonography to assess the 
patency of the pOr1al and suprahepatic veins, an abdominal 
computed tomographic scan for measurement of Ii .. er vol-
ume, viral hepatitis and toxic screens, urine copper excre-
tion, and serum ce'l.jloplasmm level. All potential infection 
must be avoided, and an~D eXist 109 mfection must be treated 
early and aggresSl\ ely. The coagulation status should be 
corrected as much.H possible With fresh frozen plasma (FFP) 
infusions and the administration of exogenous vitamin K, 
while renal function must be gUcHanteed, and nutritiondl 
status must be mamtained via enteral or parenteral route$, 
using hepatoprotec!lve formulas. If the patient is obtunded, 
nasogastric suction is recommended to prevent aspiration 
pneumonia, and the stomach pH should be kept alkaline by 
administration of antacids and/or histamine-2 blockers. 
Should any doubt ex:st as to the possibility of aspiration, the 
patient's aiM'ay ml.ist be protected with prophylactic intu-
bation. Any increase in the intracranial pressure must be 
prevented and controlled, at the earliest signs of onset. by 
hyperventilation and mannitol infusion, provided that rtoNI 
function is adequate; if kidney function is impaired, ultrafil-
tration can be used to rid the patient of extri fluid. Plasrn.J-
pheresis or charcoal hemofiltration may be used as tempo-
rizing measures. particularly in the case of drug toxicity or 
fulminant Wilson's disease. 
Another extremely important point is that any patient with 
FHF /SAF must be transferred to a center that performs liye/' 
transplantation procedures early in the course of their dis-
ease, so that they can be monitored adequately, worked up, 
and (if necessary) transplanted under optimil conditions. It 
is unfortunate that. all too often, the transfer takes place y~~ 
late, after everything else has failed at the original hosPlt 
and when the patient's condition is too advanced to alloW 
successful transplantation_ 
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Intraoperati\'e Management 
The inrraoperative management of patients with FHF ISAF 
unrK~rgoing transplantation is a titanic effort that requires the 
full and exclusive involvement of the surgical and anesthe-
siologic teams. Technically. transplantation under these 
conditions is not extremely challenging, since these patients 
do not usually have any adhesions (rom previous surgery or 
portal hypertension. On the other hand, given the precari-
ous, if not plainly terminal condition of the patient. the 
operation must be done in a virtually perfect fashion to 
avoid large blood losses and/or hypotension. which could 
cause irreversible damage to the brain al!eady at risk from 
er:cephalopathy or coma. But. while the operation is not a 
~ajor technical challenge. in some cases cross-clamping of 
the portal vein and inferior vena cava, with the obligatory 
reduction of the venous return to the heart to less than half 
the normal levels can be disastrous. particularly in a patient 
with cerebral edema and advanced hepatic encephalopa-
thy. This was one of the most important factors in explaining 
the dismal results of liver transplantation for FHF /SAF during 
the "pioneer" years. The introduction of veno-venous by-
pass. therefore, has had a major impact on improved sur-
, ivai during the last few years. 
The main challenge of liver transplantation for FHF jSAF 
really rests with the anesthesia team who must deal with and 
correct all the imbalances related to a state similar to that 
found in septic shock (increased cardiac output and de-
creased peTipheral vascular resistance), compounded by 
severe coagulopathy, acid-base imbalances. renal dysfunc-
tion With a decreased or absent urlOe output. and many 
electrolvte abnormalities. The electrol~ te and coagulation 
imbalances are particularly severe at the end of the anhepa-
tiC phase of the operation. The anesthesia team is therefore 
faced With a highly comple)( situation reqUIring unfaltering 
attention throughout the procedure. The correction of tluid 
and electrolyte abnormalities is done continuously; coagula-
tion is also monitored by means of thromboelastograms 
(TEC) and corrected as needed with fresh frozen plasma, 
platelets. cryopreclpitates and/or epsilon-aminocaproic 
acid. Intraoperative electroencephalogram (EEC) monitor-
ing is recommended. since the presence of seizure activity 
cannot be otherwise ascertained under general anesthesia. 
although this requires either an HG technician or an anes· 
thesiologist versed in EEC interpretation. Vasopressors to 
control hypotension during the operative procedure must 
be administered extremely cautiously since they can dam-
age the allograft by decreasing splancnic blood flow_ 
The postoperative management of patients transplanted 
for fHF ISAF is different from that of other liver transplant 
patients. SpeCifically. they may still have residual renal fail· 
ure. requiring adjustment of their cyclosporine (CsA) doses. 
As a result. they may require the addition of other immuno-
suppressive agents to compensate for the lower CsA level 
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Figure 2. The male/female ratio in this senes. 
(azathioprine, antithymocyte globulin (ATC), or a mono-
clonal antibody pre~a~aD :n (OKT3)). Hemodialysis is neces-
sary at times until re~ _ iunction recovers. In such cases, 
liver function must be monitored more carefully than is 
usual since primar\ "'c.-junction of the allograft tends to be 
more lethal in pal ~rKts \\hose brain is already impaired as a 
result o( preexisting encephalopathy. If the allograft (unction 
during the early postoperative period is not e)(cellent, re-
transplantation should be done as an emergency to limit 
further patient deterioration. A characteristic, although fairly 
rare complication of fulminant non-"', non-8 hepatitis is 
aplastic anemia, which can be observed before or after 
transplantation. While generally reversible. this condition 
can be intrinSically fatal. On the other hand, the reduction in 
immunosuppression necessary during the period of maxi-
mal leucocyte count depression may lead to severe rejec-
tion once the leukocyte count returns to normal levels. 
Results of Uver Tr.lnsplanl.ltion (or fHF/SAf 
Our experience includes a subset of 47 of 1000 patients 
who underwent liver transplantation for FHF /SAF utilizing 
cyclosporine/prednisone therapy between March 1980 and 
July 1987_ Of these 47 patients. 21 (43.5%) were male and 
26 (56.5%) were female (Figure 2). Their ages ranged from .. 
to 62 years (overall mean. 22.02). with a range of .. to 62 
years (mean, 20.30) (Of males and a range o( 6 to 60 years 
(mean, 23.35) (or ferNles (Figure 3)_ Nine patients (19.1%) 
had hepatitis type B (three males and six females); 20 
(42_5%) had hepatitis type non-A, non·S (nine tN/es. 11 
females); six (12_9%) h.ld fulminant chemal toxicity (four 
males, two (erNles); ten (21_3%) h.ld fulmiNnt Wilson's 
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Figure 3. Age distnbutlOn 01 the patients: generany speaking. two 
peaks are noted. one II'l the second to thlfd decades and another one 
in the sillth decade. 
disease (four male~K Sill females); one female (2.1 oro) had FHF 
oj unkno ..... n etiology (possibly Reye's syndrome); and one 
male (2.1°1b) had acute hepatic insufficiency secondary to 
ligation of the hepatic artery during surgery for pheochro-
mocytoma (Figure 4). Thirty-five (73%) had FHF (17 males 
and 18 females), and 12 (2 i%) had SAF (four males and eight 
females) (Figure 5). Se .... en (14.9%) had very mild or no en-
cephalopathy, nine (19.1 %) had grade I hepatic coma, 
seven (149%) had grade II hepatic coma, nine (19.1 %) had 
grade III hepatiC coma. and 14 (32%) had grade III/IV or IV 
coma (Figure 6). The inter.al from the onset of clinical dis-
ease to the time of tramplantation ranged from 0 to 25 
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Flgur. 5. Ratio of acute versus subacute presentation ... ttU series 
and respe<:tive raw mortality. 
weeks (mean, 5.11 :: 5.19). the total pretransplant hospi-
tal time ranged from less than 1 to 45 days (mean, 10.91 
:: 11.521. the pretransplant intensive care (leU) time ranged 
from 0 to 11 days (mean, 2.11 :: 2.29), ",hile the time spent 
on a respirator before transplantation ranged from 0 to 5 
days (mean, 0.86 :: 1.11). Twenty-six patients (55.4%) sur-
vived (12 males and 14 females), while 17 (44.6%) died 
(nine males and eight females) (Figure 7). There was no 
significant statistical difference in the total pretransplant, 
hospital, and leu time between the survivor and nonsurvi-
vor groups. A trend toward a longer time spent on the respi-
rator before transplantation was evident in nonsurvivors 
(0.71 :: 0.86 days for survivors versus 1.05 :: 1.36 days for 
nonsurvivors) although the number of patients in this group 
was too small to achie .... e stallstical significance. No mean 
age difference was noted between survivors and nonsurvi-
vors (22.35 versus 21.60 years). 
Of the 47 patients in our series, 28 (59.5%) had a good 
neurologic outcome, meaning a complete recovery of their 
neurological atld intellectual performance, without any evi-
dence of neurologic sequellae; three patients (6.3%) had a 
fair neurologic outcome, with persistence of some sequel. 
lae, and, finally, 1 b patients (34.2%) had a poor outcome 
(Figure 8). This latter group included all the nonsurvivors, 
who never awoke after the transplant operation and two 
patients who survived for at least 6 months or longer but 
never regained sufficient capacity to function indepen. 
dently. There was no statistical difference in the total pre-
transplant, hospital. and leu time between the patients with 
a good and a poor neurologic outcome; there was a trend 
toward a difference between the two groups when the time 
spent in the leu and on a respirator preoperatively was 
considered (1.96 ± 2.65 days for a good outcome versus 
2.20 ± 1.70 in the leu for a poor outcome and 0.58 ± 0.67 
days versus 1.40 ± 1.40 days on a respirator, respectively). 
The number of patients in each group, however, was too 
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Flgur. 6. The proportion of patients presenting With the various 
degfe1:!S of encephalopathy/coma. 
low to achieve statistical significance. A notable difference 
between good and poor neurologic outcomes was observed 
when the degree of coma \\as analyzed: eight of 16 patients 
with a poor outcome (50%) had grade III/IV or IV coma, 
while only six of 28 (21.4010) patients with a good outcome 
had advanced coma. 
Discussion 
Given the otherwise dismal prognosis, liver transplanta-
tion is a particularly attractive alternative for FHF /SAF. Until 
just a few years ago this was not feasible in practice since the 
results of liver transplantation in general were rather poor, 
and the additional handicaps associated with FHF only 
compounded the problem. Since the introduction of CsA to 
the transplantation armamentarium, results of liver trans-
plantation have improved enormously (Figure 9). As most 
patients with FHF, regardless of etiology, have a survival of 
only 20% or less with even the most intensive medical 
treatment, while transplantation offers immediate survival of 
at least 55%, this form of therapy evidently offers a distinct 
advantage. In addition, the greater availability of donors has 
made liver replacement for FHF a reasonable proposition. 
All other available methods of temporary hepatic support 
have only provided additional time during which a donor 
organ can be sought actively, although none represents a 
valid definitive alternative to liver transplantation. These 
methods should be used routinely, however, whenever pos-
sible during the pretransplant period to slow the progression 
of the hepatic failure, thus allowing the patient to be trans-
planted while still in the best possible condition. Especially 
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Figure 7. Raw svrvivaJ. in general and by sex distribution. 
valuable in this respect are the use of activated charcoal 
hemofiltration. plasmapheresis, and prostacycline infusion 
for prevention of platelet aggregation.1.1 
It is interesting that all cases of FHF due to hepatitis B virus 
infection but one have had recurrence of the disease, al-
though not usually," a fulminant form. The first periopera-
tlve prKrvfsl~ of a transplant for hepatitis Band FHF (surgerv 
done," 191 ~F appeared to be hepalills B negative by ra-
dioimmunoassay after the procedure. Subsequent records 
for this patient are, unfortunately, incomplete. and he died) 
months later of complications of the transplant unrelated to 
hiS anginal disease. One patient died on the operating table. 
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Figure 9. Actuarial survival for patients with FHF/SAF. 
All the others (62500) have continued to be serologically 
positive alter the transplant, many with biopsy-proven re-
currence of the disease. All but one are stable and well now, 
although", Ith active low-grade disease, 8 months to 3 years 
after their transplant. One patient has had retransplantatlon 
for chronic active hepatitis B. 
As in prevIous studies,' a remarkable negative impact of 
retransplantatlon on survival was observed, particularly 
'" hen the retransplantation was necessary because of pri-
mary graft non· function (figure 10). Interestingly enough, in 
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Flgur. 10. Differences in aetuatllll survIVal for the varIOUs etoOlc> 
gies for FHF/SAF. Rej .• r!JeCbOn. Although rejectiOn and pnmaty 
not\function (PNF) are not Iht original causes of fulminant hepatic 
faaure in this senes. the mor1aity sec:ondaty to these conditiOns after 
the transplant is shown to demonstrate their impact. 
this series the only pallent who received four consecutive 
liver transplants survived. In this conte).t. it appears that the 
need for very early retransplantation adversely affects sur. 
vival. This can be explained by the devastating effect of ~ 
poor quality graft on an already impaired brain. 
Of all types of FHF, toxic hepatitis seems to have the 
poorest prognosis: only one oi six patients (16.6%) has sur-
vived. In fact, one young woman, transplanted after sudder. 
omet of rapidly deteriorating liver failure after exposure 10 
volatile substances, now has what appears' 10 be a low-de-
gree chronic hepalitis, with negative viral hepatitis screen. 
suggesting that she may have had non-A, non-S hepatitis 
from the outset. Without this case, there would be no SUrvi-
vors from fulminant chemical hepatitis in our series. ThE" 
main reason for this phenomenon is that these forms o' 
hepatic failure can be extremely rapid in their progreSSion te 
irreversible coma; if the patient is not transferred immedI-
ately to a center capable of liver transplantation, the fulmi-
nant course will deny them the benefit of this life-saving 
form of therapy. 
A slight, although not statistically significant increase 0: 
mortality among female patients (46.2% \ersus 42.9%) wa~ 
noted. This probably represents an artefact (Figure 7). The 
same observation can be made about the small difference Ir' 
mortality (or patients with acute or subacute hepatitl~ 
(44.4% versus 50%, respectively) (Figure 5). 
In light of our data. as well as that oi others, there is lillll.' 
doubt that liver transplantation for FHF ISAF is nol. only jus-
tified but indicated. The continuous progress made in earl\ 
diagnosis. patient selection, technique, postoperative care. 
and immunosuppression means that transplantation shoul!:! 
be offered as an alternative earlier than ever before, and Ir. 
some cases, even before spontaneous recovery can be ruled 
out completely. 
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